Development of a screening diagnostic for the detection of viruses and bacteria from body fluids that utilizes the unparalleled structural characterization of mass spectrometry

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1R21AI178442-01

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2023.0
    2025.0
  • Known Financial Commitments (USD)

    $241,356
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    RESEARCH PROFESSOR Aaron Timperman
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF PENNSYLVANIA
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Project Summary/Abstract The long-term goal of this project is to develop of a rapid, inexpensive, and sensitive screening diagnostic based on an innovative broad proteomic approach to improve our ability to diagnose infectious disease, monitor changes in the microbiome, measure the state of the host immune system, and identify disease specific biomarkers. Specifically, the initiative will provide proof of principle for a method to achieve simultaneous multi-pathogen detection and deep proteomic microbiome characterization. We will work to detect the presence of several hundred pathogens while also identifying thousands of microbes at clinically relevant levels. The short amino acid sequences or peptides from the proteins will provide markers that range from the virus variant level, such as SARS- CoV-2 variants of concern, to the family level, such as coronaviridae. In developing this diagnostic, a key challenge is to maximize the sensitivity of peptide marker detection while analyzing for many clinically relevant viruses and bacteria. We will therefore compare the performance of (a) a data-dependent acquisition method that searches a custom database and (b) a data-independent acquisition method that can identify thousands of proteins. The proposed study will begin with the analysis of approximately twenty model pathogens before proceeding to the more ambitious analysis of more than 230 oro-respiratory samples. We will assess the primary factors that determine the performance of each method and use our milestones to select one approach for further development. In the end, this research will demonstrate the feasibility of a broad protein-based screening diagnostic that can detect numerous pathogens and provide microbiome profiling to ultimately improve the diagnosis of disease and assessment of human health. The project team includes researchers with diverse expertise from Penn Engineering, Microbiology, and Penn Medicine.